Navigation Links
Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
Date:4/14/2009

rivately-held, venture-backed development stage company developing proprietary biotherapeutic products and tools to address the unmet clinical needs of millions of patients suffering from cardiac disorders. Headquartered in Orange County, California, the Company's products employ proprietary biocompatible polymers delivered into specific locations of the heart during either open chest surgery or via a minimally invasive procedure. The biopolymers are engineered to achieve clinical benefit by locally modifying cardiac physiology. Symphony's products are classified by the FDA as devices and have a clear regulatory pathway and clinical end points.

The Company has two products in its late-stage development pipeline - Algisyl-LVR(R) for the treatment to prevent or reverse the progression of chronic heart failure (CHF) and mitral valve regurgitation (MR), conditions affecting well over 5 million Americans. Symphony's approach involves implanting a space-occupying biocompatible polymer into strategic areas of the heart's left ventricle (LV) wall to affect LV shape and prevent or reverse LV enlargement. Reshaping and thickening the LV wall reduces wall stress, reduces mitral valve regurgitation and provides lasting improvement of cardiac function with an associated improvement in the patient's clinical status and quality of life. Algisyl-LVR has advanced to human clinical studies with a first-in-man study initiated in February 2009. Plexisyl-AF(R) a prophylactic method of preventing sustained post-operative atrial fibrillation (POAF), a common side effect of the approximately 1 million coronary bypass and cardiac valve replacement surgeries performed each year. Plexisyl has advanced to human clinical stage testing. A 32-patient safety study was completed in Europe in May 2008.

For more information on Symphony Medical please visit our website at www.symphonymed.com.

'/>"/>
SOURCE Symphony, Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Symphony Managemnt Consulting Hires New Solutions Director
2. Angiotech and Symphony Medical Announce Licensing Agreement
3. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
4. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
5. Ventus Medical Appoints John McCutcheon as President and CEO
6. New security and medical sensor devices made possible by metallic nanostructures
7. Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for Best and Brightest Forum on Medical Innovation
8. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
9. SPO Medical Files Annual Report for Fiscal 2008
10. ArunA Biomedical Submits Contract Proposal to Further Develop Environmental Biosensor for National Security
11. ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015  Ardelyx, Inc. (NASDAQ: ... on cardio-renal, gastrointestinal and metabolic diseases, today announced ... joined the Company,s Board of Directors. Dr. Jenkins ... level experience, having built and led teams advancing ... approval and into healthcare systems globally. ...
(Date:4/20/2015)... 20, 2015 - Development of ... Using the VOLVOX Platform - To be Presented on ... -  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 ... on Sunday, Apr 19, 1:00 PM EST ... program, today announced that the company,s novel computational platform ...
(Date:4/20/2015)... 2015 Global Stem Cells Group ... 2015, an annual gathering of aesthetic medicine experts and ... scheduled to introduce the company’s brand new training course ... stem cell techniques. , The course is designed ... the aesthetic field, including facial aging caused by volume ...
(Date:4/17/2015)... Reed Technology and Information Services ... management, preparation, and submission to the U.S. Food and ... new Lot Distribution Report (LDR) service for manufacturers of ... with the FDA’s new rule on electronic submission of ... the volume and timing of particular biologics introduced to ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
... 2011 HumanTouch, LLC today announced that they were ... Contractors list.   The Fast 50 list ... market conditions and build a sustainable business.  As Washington ... Fast 50 range from resellers to consultants and IT ...
... Resonetics introduces the RapidX250 laser micromachining system, developed ... MEMs and medical devices in a rapid prototype ... devices are fabricated by traditional semiconductor lithography but ... uses a multi-wavelength excimer laser (193nm and 248nm) ...
... Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... Department of Defense (DOD) contract to develop its human ... brain tumors. The research contract, entitled "Research to Treat ... carried out in collaboration with Principal Investigator John Zhang, ...
Cached Biology Technology:RapidX250 Rapid Prototype Tool for Micro Fabrication of Microfluidics, MEMs and Medical Devices 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... for new antibiotics: A new research published in the July ... http://www.fasebj.org ) explains for the first time how honey kills ... that they add to the honey, called defensin-1, which could ... and to develop new drugs that could combat antibiotic-resistant infections. ...
... WEST LAFAYETTE, Ind. - Fast-food restaurants can supersize French ... to supersize a type of apple. Peter Hirst, a ... in some Gala apple trees causes some apples to grow ... reported in the current issue of the Journal of ...
... A drug used to treat rheumatoid arthritis also reduces ... lab research and preliminary findings from a clinical trial of ... clinical study to refine the drug anakinra,s use as an ... Nancy Rothwell will summarise her team,s latest research into both ...
Cached Biology News:Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria 2Apples grow larger when cells don't divide, study shows 2New hope for victims of stroke 2
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
... LYZL6 ( Abpromise for all ... Synthetic peptide: DWLCL AFVE SKFNISKINE ... to amino acids 46-100 of Human ... ID: 57151 ...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Biology Products: